Phase-I open label, dose-escalation clinical trial to evaluate the safety, tolerability and immunogenicity of Chikungunya vaccine in healthy adults of 18 to 50 years age - Chikungunya vaccine

Trial Profile

Phase-I open label, dose-escalation clinical trial to evaluate the safety, tolerability and immunogenicity of Chikungunya vaccine in healthy adults of 18 to 50 years age - Chikungunya vaccine

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2017

At a glance

  • Drugs Chikungunya virus vaccine (Primary)
  • Indications Chikungunya virus infections
  • Focus Adverse reactions
  • Sponsors Bharat Biotech
  • Most Recent Events

    • 22 May 2017 Status changed from not yet recruiting to recruiting.
    • 14 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top